| Eden and GenoPalate Announce Strategic Partnership to Redefine the Future of GLP-1 Care |
Contact Chris Connell Director of Marketing & Partnerships chris.connell@genopalate.com MILWAUKEE, WISCONSIN, Wednesday, May 13, 2026 — GenoPalate, a personalized nutrition company helping people turn biological data into practical nutrition guidance, today announced a strategic partnership with Eden, a telehealth platform that connects individuals with licensed providers to explore GLP-1 treatment options for weight management. The partnership brings together two critical parts of the modern GLP-1 experience: access to licensed medical providers and medication through Eden and personalized nutrition support through GenoPalate. Together, the companies aim to help individuals better navigate not only whether GLP-1 medication may be appropriate, but also how to support their nutrition, habits, and long-term wellness throughout the journey. Through the partnership, GenoPalate members will have access to Eden’s telehealth pathway to determine whether GLP-1 medication may be appropriate for their individual health profile. Eden members will also be introduced to GenoPalate’s new Thrive on GLP-1 wellness program, a four-month, expert-led program that uniquely combines multiomic analysis, expert nutrition guidance, and targeted, custom-formulated supplementation that can adapt based on continuous inputs from each member’s biology, habits, and progress. “At Eden, we believe people deserve a more complete and supportive experience when exploring GLP-1 treatment,” said Josh Khan, Co-Founder of Eden. “Our role is to help connect individuals with licensed medical providers who can evaluate whether medication is appropriate. By partnering with GenoPalate, we’re helping extend and enhance that journey with personalized nutrition support that can make care feel more practical, informed, and sustainable.” The partnership comes as both Eden and GenoPalate see growing demand from members looking for more support before, during, and after starting GLP-1 medication. Many are not only asking whether GLP-1s are right for them. They are asking how to eat with a reduced appetite, how to maintain protein intake, how to protect muscle, how to manage nutrient gaps, how to navigate side effects, and how to build habits that support long-term weight management. “GLP-1 care is entering its next chapter,” said Dr. Asif Naseem, CEO of GenoPalate. “Access to medication is important, but it is only one part of the journey. People need to understand what their body requires, how to nourish themselves with a reduced appetite, how to manage changes along the way, and how to build habits that support lifelong wellness. That is where science-based personalized nutrition, biomarker data, and expert coaching become essential.” The partnership reflects a shared belief that the next phase of GLP-1 care will require more than access alone. By connecting medical evaluation with personalized nutrition support, GenoPalate and Eden are helping create a more practical, guided, and sustainable model for individuals navigating weight management. |
| ### About GenoPalate GenoPalate is a personalized nutrition company helping individuals better understand their unique biology through science-backed insights and practical nutrition guidance. By combining advanced biological analysis with personalized recommendations, coaching, and tools for action, GenoPalate is helping shape the future of personalized nutrition and prevention-focused wellness.About EdenEden is a health platform built to extend health span through connecting individuals with personalised, physician-guided programs that may combine personalised medications, lifestyle coaching, and community support through independent, licensed physicians. Eden connects members to licensed providers and pharmacists through a single integrated ecosystem. |
